Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.
You may also be interested in...
Glaxo Unloads Lucozade, Ribena Nutritional Beverages
GlaxoSmithKline’s latest consumer business divestment, of Lucozade sports beverages and Ribena fruit drinks, reflects the company’s focus on pharmaceuticals and emerging markets, between which the beverage brands were somewhat lost.
Glaxo Unloads Lucozade, Ribena Nutritional Beverages
GlaxoSmithKline’s latest consumer business divestment, of Lucozade sports beverages and Ribena fruit drinks, reflects the company’s focus on pharmaceuticals and emerging markets, between which the beverage brands were somewhat lost.
China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.